Amgen Inc (AMGN.US) is joining a new 340B rebate pilot program with other major pharmaceutical companies like AbbVie, Pfizer, and GSK. This initiative aims to improve drug pricing and accessibility for low-income patients through the 340B Drug Pricing Program. Recently, Amgen's stock closed at $398.40, showing a slight decrease of 0.01% in the latest trading session.
Investor takeaway: Keep an eye on developments related to this pilot program and how it might affect Amgen's market position and financial performance.
Amgen's Stock Volume at 448,121 Shares, Below Average
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$217.90B
P/E
25.1x
Div. yield
2.41%
Div. / share
$9.80
52W high
$447.03
52W low
$280.23
1W change
-3.62%
Beta
0.43
Analyst Price Targets
Based on 34 analysts covering AMGN · as of Oct 5, 2026
Wall Street analysts forecast AMGN stock price to fall 3.0% over the next 12 months.
Consensus
Hold3.35 / 5.00
Avg. Target
C$390.94
-3.0% Upside
Current Price
C$402.98
Last close
Analyst Breakdown (34 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
39.3%
Annualized
90-Day Vol
32.4%
Annualized
Trend (90d)
+45.9%
Annualized drift
90d Mean
C$474.73
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$425.60 | C$371.62 – C$487.42 |
| 60 trading days | C$449.49 | C$371.04 – C$544.53 |
| 90 trading days | C$474.73 | C$375.34 – C$600.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Amgen's trading volume of 448,121 shares is significantly lower than the 20-day average of 3,327,380 shares, indicating reduced trading activity.
Details of the 340B Rebate Pilot
The 340B rebate pilot program aims to make medications more affordable for low-income patients. Amgen, along with AbbVie and Pfizer, is working to navigate the complexities of drug pricing while adhering to federal regulations. While specifics and the timeline for this pilot are still under wraps, such initiatives are crucial as drug affordability becomes a growing concern. Investors should watch how this program develops and its impact on Amgen's market engagement.
Advertisement
Current Stock Performance
In the latest trading session, Amgen's stock closed at $398.40, reflecting a slight decrease of 0.01%. Over the past week, the stock has dropped by 3.62%, and it has decreased by 7.83% over the last month. However, year-to-date, the stock is up 25.51%. The trading volume of 448,121 shares is notably lower than the 20-day average of 3,327,380 shares, suggesting decreased investor interest or market activity. Currently, the stock is positioned 71% of the way through its 52-week range of $280.23 to $447.03.
What to Watch Next
Looking ahead, investors should monitor updates regarding the 340B rebate pilot and its potential effects on Amgen's pricing strategies and revenue. Analysts have an average target price of $390.94 for Amgen, indicating a slight decline of 1.9% from current levels. The company's P/E ratio is 25.06, with a profit margin of 22.9% and a return on equity (ROE) of 91.5%. Keeping track of changes in trading volume and stock performance could provide further insights into market sentiment.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
